Bristol-Myers Halts Clinical Trials Over Patient Safety Concerns

Bristol-Myers Squibb announced it has suspended clinical trials of a drug in development for the treatment of hepatitis C.

Advertisement

 

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

The company halted the clinical trials due to “the emergence of a serious safety issue,” though officials stayed mum on the exact risk posed to patients.

More Articles on Patient Safety:

3 Ways Healthcare Quality Data Can Be Misleading

ASCA Publishes Quality Measure Reporting FAQs

CMS Adds Imaging Efficiency Measures to Hospital Compare

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.